Who is the CEO of SeouLinBioscience?

According to the DART company overview, SeouLinBioscience's representative director is 황을문, 강미옥 (각자 대표이사) (name as registered in Korean). The company was founded on 1994-04-01.

Where is SeouLinBioscience listed?

SeouLinBioscience trades on the Korea Exchange KOSDAQ market under the ticker 038070. Its fiscal year ends in December.

Does SeouLinBioscience pay a dividend?

Yes. For fiscal 2025, SeouLinBioscience paid a cash dividend of ₩100 per common share, a 1.5% yield as stated in its annual report, with a payout ratio of 117.8%. The prior year's dividend was ₩100.

Which companies are in the same industry as SeouLinBioscience?

Under the Korean Standard Industrial Classification recorded on DART, SeouLinBioscience is grouped with 36 other listed companies in wholesale trade. The most covered in Korean news over the past 30 days are Samsung C&T, Jindo and SK Gas.

SeouLinBioscience KRX:038070KOSDAQ

서린바이오 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days0

DART filings, 7 days0

Articles tracked8since Sep 11

In Q2 2026, SeouLinBioscience reported revenue of ₩20.8bn, up 28.2% year on year, and an operating loss of ₩597m. SeouLinBioscience (서린바이오) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 2 with 1 article.

SeouLinBioscience quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩20.8bn	+28.2%	−₩597m margin −2.9%	₩342m
Q1 2026	₩19.5bn	+8.3%	₩175m margin 0.9%	₩151m
Q4 2025 derived	₩20.0bn	+1.8%	₩142m margin 0.7%	−₩404m
Q3 2025	₩22.9bn	+33.5%	₩785m margin 3.4%	₩755m
Q2 2025	₩16.2bn	-18.0%	−₩332m margin −2.0%	−₩68m
Q1 2025	₩18.0bn	-4.4%	₩97m margin 0.5%	₩291m
Q4 2024 derived	₩19.6bn	-25.4%	−₩196m margin −1.0%	₩1.7bn
Q3 2024	₩17.1bn	-12.4%	₩152m margin 0.9%	₩240m

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

SeouLinBioscience top stories 2 weeks, by number of outlets

1
K-바이오 성장의 숨은 주역… 서린바이오, 연구·생산 필수 소재 솔루션 다변화
1 outlets · 1 articlesFirst report Oct 2 14:59 핀포인트뉴스

Latest SeouLinBioscience news Korean headlines

Oct 214:59

K-바이오 성장의 숨은 주역… 서린바이오, 연구·생산 필수 소재 솔루션 다변화
핀포인트뉴스
Sep 2917:29

서린바이오, 전남산림연구원과 기능성 소재 공동개발 MOU
조선비즈Partnership
Sep 2915:47

서린바이오, 산림자원 기능성 소재 개발 맞손
딜사이트TV
Sep 1613:55

서린바이오, 시간당 1200ℓ 살균수 생산 '에코트리-L' 출시
파이낸셜포스트
Sep 1610:24
서린바이오, 현장발생형 살균수 제조장치 '에코트리-L' 출시
뉴시스경제
3 more on this story · 2 outlets
- 서린바이오, 대용량 살균수 제조장치 ‘ecoTree-L’ 출시이데일리 · Sep 16 17:32
- 서린바이오, 대용량 살균수 제조장치 ‘ecoTree-L’ 출시이데일리증권 · Sep 16 17:32
- 서린바이오, 대용량 살균수 제조장치 ‘ecoTree-L’ 출시이데일리 · Sep 16 17:34

Articles per day 2 weeks

Company profile

CEO: 황을문, 강미옥 (각자 대표이사)
Industry: Wholesale trade
Founded: 1994-04-01
Fiscal year-end: December
Head office: 경기도 성남시
Website: seoulin.co.kr
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

SeouLinBioscience dividends annual report

Korea dividend rankings

Year	Per share	Yield	Payout
FY2025	₩100	1.5%	117.8%
FY2024	₩100	1.4%	28.9%
FY2023	₩100	1.1%	-711.3%

Same industry Wholesale trade

All in industry

Company	Latest quarter op. profit	Articles 30d
Samsung C&T	₩1.03tn	353
Jindo	−₩1.7bn	111
SK Gas	−₩43.9bn	62
Sonokong	−₩2.6bn	25
E1	₩118bn	20
Wooriro	₩2.6bn	20
SKNetworks	₩24.8bn	18
Gamsung	₩9.1bn	14

Compare SeouLinBioscience side by side with these companies

SeouLinBioscience DART filings

No filings yet.

Mentioned alongside 2 weeks

No co-mentioned companies yet.

SeouLinBioscience FAQ

Who is the CEO of SeouLinBioscience?: According to the DART company overview, SeouLinBioscience's representative director is 황을문, 강미옥 (각자 대표이사) (name as registered in Korean). The company was founded on 1994-04-01.
Where is SeouLinBioscience listed?: SeouLinBioscience trades on the Korea Exchange KOSDAQ market under the ticker 038070. Its fiscal year ends in December.
What were SeouLinBioscience's latest quarterly results?: In Q2 2026, SeouLinBioscience reported revenue of ₩20.8bn, up 28.2% year on year, and an operating loss of ₩597m. Figures come from reports filed on DART.
Does SeouLinBioscience pay a dividend?: Yes. For fiscal 2025, SeouLinBioscience paid a cash dividend of ₩100 per common share, a 1.5% yield as stated in its annual report, with a payout ratio of 117.8%. The prior year's dividend was ₩100.
Which companies are in the same industry as SeouLinBioscience?: Under the Korean Standard Industrial Classification recorded on DART, SeouLinBioscience is grouped with 36 other listed companies in wholesale trade. The most covered in Korean news over the past 30 days are Samsung C&T, Jindo and SK Gas.